Funded Tech Companies
Kynexis
Headquartered in Naarden, Kynexis has funding from Novartis Venture Fund, Forbion Capital Partners and Sunstone Life Science Ventures.
Company Overview
Company Name
Kynexis
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Gooimeer 2-35
Naarden, 1411 DC
The Netherlands
Naarden, 1411 DC
The Netherlands
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Kynexis is advancing a potential first-in-class approach to restore cognitive function for people living with brain diseases. The company is developing KYN-5356, a first-in-class KAT-II inhibitor designed to lower elevated kynurenic acid (KYNA), a key biological driver of cognitive impairment in disorders including schizophrenia and Alzheimer's disease. By targeting this novel pathway, KYN-5356 is designed to restore the signaling required for normal cognitive function. KYN-5356 is currently being evaluated in a Phase 2 clinical trial for cognitive impairment associated with schizophrenia (CIAS), with development expanding into Alzheimer's disease. At Kynexis, we are driven by a simple purpose: improving cognition to enable a better life for people with brain diseases.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
8/19/2026
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kees Been
Chief Financial Officer
Amy Archambault
Chief Medical Officer
Jens Wendland
VP - Bus. Development
Nick DeMartinis
VP - Bus. Development
Neil Swami
VP - Operations
Lauren Cortellessa
VP - Regulatory Affairs
Cheryl New
Company Investors
- Novartis Venture Fund (Marianne Uteng)
- Forbion Capital Partners (John McDonald)
- Sunstone Life Science Ventures
- Ysios Capital
Browse more funded tech companies:
Share this article
About Our VC Deals Database
This tech company profile is powered by VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs